Porth's Essentials of Pathophysiology, 4e

276

Hematopoietic Function

U N I T 3

R E F E R E N C E S

18. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf. 2004;27:1243–1252. 19. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J. 2005;3:14–18. 20. Mannucci PM, Tuddenham EGD. The hemophilias: from royal genes to gene therapy. N Engl J Med. 2001;344:1773–1779. 21. Carcoa M, Moorehead P, Lillicrap D. Hemophilia A and B. In: Huffman R, Benz EJ Jr, Silverstein LE, et al., eds. Hoffman Hematology: Basic Principles and Practice . 4th ed. London, UK: Elsevier Churchill Livingstone; 2013:1940–1960. 22. Lillicrap D. Von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122:3735–3740. 23. Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med. 2004;351:683–694. 24. Soliman DE, Broadman LM. Coagulation defects. Anesthesiol Clin. 2006;24:549–578. 25. Sadler JV. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173–180. 26. Klinge J, Ananyeva NM, Hauser C, et al. Hemophilia A: from basic science to clinical practice. Semin Thromb Hemost. 2002;28:309–322. 27. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90:2515–2521. 28. Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematology. 2009:240–246. 29. Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J. 2006;4:4–12. 30. Van der Poll T, Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:639–651. 31. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191–2195.

1. Hall JE. Guyton and Hall Textbook of Medical Physiology . 12th ed. Philadelphia, PA: Elsevier Saunders; 2011:451–461. 2. Ross MH, Kaye G, Pawlina W. Histology: A Text and Atlas . 6th ed. Philadelphia, PA: Wolters Kluwer Health | Lippincott Williams & Wilkins; 2011:269–289, 271–272. 3. Kumar V, Abbas AK, Fausto N, et al. Robbins and Cotran Pathologic Basis of Disease . 8th ed. Philadelphia, PA: Saunders Elsevier; 2010:115–125, 666–675. 4. Valdez R, Zutter M, Flores AD, et al. Hematopathology. In: Rubin R, Strayer DS, eds. Rubin’s Pathology: Clinicopathologic Foundations of Medicine . 6th ed. Philadelphia, PA: Wolters Kluwer Health | Lippincott Williams & Wilkins; 2012:947–998. 5. Weitz JI. Overview of hemostasis and thrombosis. In: Huffman R, Benz EJ Jr, Silverstein LE, et al. Hoffman Hematology: Basic Principles and Practice . 4th ed. London, UK: Elsevier Churchill Livingstone; 2013:1774–1783. 6. Messmore HL, Jeske WP, Wehrmacher W, et al. Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am. 2005;19:87–117. 7. Zehnder JL. Drugs used in disorders of coagulation. In: Katzung BG, ed. Basic and Clinical Pharmacology . 12th ed. New York, NY: McGraw-Hill; 2012:601–618. 8. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938–949. 9. Schafer AI. Thrombocytosis. N Engl J Med. 2004;350:1211–1219. 10. Bloomenthal D, von Dadelszen P, Liston R, et al. The effect of factor V Leiden carriage on maternal and fetal health. Can Med Assoc J. 2002;167:48–54. 11. Chrousos GP. The gonadal hormones and inhibitors. In: Katzung BG, ed. Basic and Clinical Pharmacology . 12th ed. New York, NY: McGraw-Hill; 2011;715–739. 12. Levine JS, Branch DW, Rausch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752–763. 13. Hanly JC. Antiphospholipid syndrome: an overview. Can Med Assoc J. 2003;168:1675–1682. 14. Lin W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome. JAMA. 2006;295:1050–1057. 15. Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med. 2008;359(12):1261–1270. 16. Bromberg ME. Immune thrombocytopenia purpura: the changing therapeutic landscape. N Engl J Med. 2006;355: 1643–1645. 17. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995–1008.

Porth Essentials Resources Explore these additional resources to enhance learning for this chapter: •  NCLEX-Style Questions and Other Resources

on

, http://thePoint.lww.com/PorthEssentials4e

• Study Guide for Essentials of Pathophysiology • Concepts in Action Animations • Adaptive Learning | Powered by PrepU, http://thepoint.lww.com/ prepu